Precision medicine is an approach to healthcare that uses information about a person's genes, biological characteristics, environment and lifestyle, together with conventional clinical information, to improve prevention, diagnosis, prognosis or treatment decisions. Rather than assuming that everyone with the same diagnostic label will respond identically to the same intervention, precision medicine seeks to identify biologically meaningful differences between individuals or disease subtypes. Genomic information is an important component, but precision medicine is not synonymous with genetic testing.
Depending on the clinical problem, precision approaches can incorporate DNA and RNA sequencing, protein measurements, immune characteristics, imaging, laboratory results, electronic health records and information about exposures or behaviour. The goal is generally to select or design healthcare strategies that are better matched to relevant biological or clinical characteristics. Precision medicine is particularly established in some areas of oncology, where molecular features of a tumour can guide the selection of targeted therapies. It is also being investigated or applied in pharmacogenomics, rare disease diagnosis, infectious disease management, cardiology and other fields.
Precision medicine is closely related to but distinct from population-based medicine. Traditional clinical guidelines often identify treatments that work well for a large group of people with a particular disease, based on evidence from clinical trials and population averages. Precision approaches attempt to identify subgroups or individual characteristics that explain differences in disease mechanisms or treatment response. A biomarker may be used to identify such a subgroup.
Biomarkers can include genetic variants, gene-expression patterns, proteins, metabolites, imaging findings or measurable physiological characteristics. In cancer, for example, the presence of a particular molecular alteration can help determine whether a targeted drug is biologically appropriate. In pharmacogenomics, inherited genetic variation can influence how rapidly someone metabolises a medicine or how strongly they may respond to it, although genetic information is only one factor affecting drug response. Precision medicine therefore complements evidence-based medicine rather than replacing it. A treatment still needs evidence of safety and effectiveness, and a biologically plausible match does not guarantee that an intervention will benefit a particular patient.
Genomic technologies have greatly expanded the capabilities of precision medicine. DNA sequencing can identify variants in genes associated with disease mechanisms or drug response, while RNA analysis can provide information about gene activity. In cancer, tumour sequencing may reveal somatic mutations, gene fusions, copy-number changes or other molecular abnormalities that distinguish one tumour from another. Germline sequencing can identify inherited variants relevant to disease risk or medication response.
Other technologies include proteomics, which measures large numbers of proteins; metabolomics, which examines metabolites; and epigenomic approaches, which investigate regulatory changes affecting gene activity. Artificial intelligence and machine-learning methods can analyse large datasets and identify patterns that might not be apparent from individual measurements. However, data quality, population representation, clinical validation and interpretability are critical. A technically accurate molecular measurement is not automatically clinically useful, and precision medicine requires validated relationships between a biomarker and a clinically meaningful outcome.
Precision medicine has several potential applications across the healthcare pathway. In prevention, genetic or other risk information may identify people who could benefit from earlier surveillance or targeted interventions, although risk prediction must be interpreted carefully. In diagnosis, molecular testing can distinguish diseases that appear clinically similar but have different biological causes. In prognosis, biomarkers may provide information about expected disease behaviour, although prognostic associations do not necessarily indicate which treatment will work.
In treatment selection, molecular features can help identify patients who may benefit from targeted drugs or who may need to avoid particular therapies because of increased toxicity risk. Precision approaches can also support dose selection, treatment monitoring and the detection of resistance mechanisms. In infectious diseases, sequencing can characterise pathogens and sometimes inform outbreak investigation or antimicrobial strategy. The practical value therefore depends on the condition, available tests, evidence supporting them and whether an actionable intervention exists.
Oncology provides one of the clearest examples of precision medicine because cancers that arise in the same organ can differ substantially at the molecular level. A tumour may contain alterations that activate growth signalling, disable tumour-suppressor pathways, alter DNA repair or create abnormal fusion proteins. Some targeted treatments are designed to interfere with particular molecular abnormalities, while immune-based treatments can depend on characteristics of the tumour and its interaction with the immune system.
Tumour profiling can therefore provide information beyond anatomical location alone. Nevertheless, cancer precision medicine has limitations: tumours can contain multiple genetically distinct cell populations, molecular profiles can change during treatment, resistance can develop, and not every detected alteration has a proven treatment. A molecular match identified in a laboratory or database may also have weaker evidence than a treatment supported by a large randomised clinical trial. Precision oncology consequently involves integrating molecular findings with pathology, imaging, clinical stage, previous treatment and the person's overall circumstances.
Precision medicine developed from several strands of biomedical research, including human genetics, molecular biology, pharmacology and advances in computing. The completion of the Human Genome Project and subsequent reductions in sequencing costs accelerated the ability to analyse genetic information at scale. The emergence of high-throughput sequencing made it increasingly feasible to study many genes simultaneously, while improvements in bioinformatics allowed clinicians and researchers to interpret complex molecular datasets.
The term precision medicine gained prominence as healthcare systems increasingly focused on using molecular and other patient-specific data to refine clinical decisions. Earlier concepts such as personalised medicine, targeted therapy and stratified medicine overlap substantially with precision medicine, although they are not identical in every context. Precision medicine often emphasises identifying biologically defined groups and actionable characteristics rather than implying that every treatment is individually designed. Its development continues as researchers integrate genomic, clinical, environmental and longitudinal health data.
Important limitations include cost, access, data complexity, uncertain findings, privacy concerns and unequal representation in research datasets. Genetic databases have historically included disproportionate numbers of people of European ancestry, which can reduce the accuracy of variant interpretation for populations that are underrepresented. Precision algorithms can also reproduce biases present in the data used to develop them. Genetic and molecular tests can produce incidental findings or variants whose clinical significance is uncertain, creating challenges for communication and decision-making.
Some biomarkers predict risk without providing an effective intervention, limiting their immediate clinical usefulness. There is also a distinction between analytical validity, clinical validity and clinical utility: a test may accurately measure a biological feature without that feature reliably predicting disease or improving patient outcomes. Precision medicine therefore requires rigorous validation, appropriate regulation, secure handling of sensitive data and continual reassessment as scientific evidence changes.
Precision medicine should not be interpreted as a promise that healthcare can become perfectly tailored to every individual. Biological systems are complex, diseases evolve and environmental factors can alter outcomes even when a relevant molecular feature has been identified. The most useful precision approaches are those in which a reliable characteristic is linked to a meaningful clinical decision and supported by evidence.
Precision medicine can reduce ineffective treatment in selected settings, help identify diseases with previously unclear causes and accelerate research into new therapies, but it can also generate false expectations if molecular testing is presented without explaining uncertainty. Its long-term development depends on combining laboratory science with high-quality clinical trials, diverse populations, appropriate data governance and careful interpretation. The central principle is therefore not simply testing more genes, but using clinically relevant biological information to make better-supported healthcare decisions.
